Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Zavegepant nasal spray for the acute treatment of migraine: A Phase 2/3 double‐blind, randomized, placebo‐controlled, dose‐ranging trial
Authors
Keywords
-
Journal
HEADACHE
Volume 62, Issue 9, Pages 1153-1163
Publisher
Wiley
Online
2022-10-14
DOI
10.1111/head.14389
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice
- (2021) Jessica Ailani et al. HEADACHE
- Guidelines of the International Headache Society for controlled trials of acute treatment of migraine attacks in adults: Fourth edition
- (2019) Hans-Christoph Diener et al. CEPHALALGIA
- Unmet Acute Treatment Needs From the 2017 Migraine in America Symptoms and Treatment Study
- (2019) Richard B. Lipton et al. HEADACHE
- Dihydroergotamine (DHE) – Then and Now: A Narrative Review
- (2019) Stephen D. Silberstein et al. HEADACHE
- Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
- (2018) CEPHALALGIA
- Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis
- (2018) David Fraguas et al. SCHIZOPHRENIA BULLETIN
- Migraine in America Symptoms and Treatment (MAST) Study: Baseline Study Methods, Treatment Patterns, and Gender Differences
- (2018) Richard B. Lipton et al. HEADACHE
- Framingham-Based Cardiovascular Risk Estimates Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study
- (2017) Richard B. Lipton et al. HEADACHE
- Faster Improvement in Migraine Pain Intensity and Migraine-Related Disability at Early Time Points with AVP-825 (Sumatriptan Nasal Powder Delivery System) versus Oral Sumatriptan: A Comparative Randomized Clinical Trial Across Multiple Attacks from the CO
- (2017) Richard B. Lipton et al. HEADACHE
- AVP-825 (Sumatriptan Nasal Powder) Reduces Nausea Compared to Sumatriptan Tablets: Results of the COMPASS Randomized Clinical Trial
- (2017) Richard B. Lipton et al. HEADACHE
- Cardiovascular Events, Conditions, and Procedures Among People With Episodic Migraine in the US Population: Results from the American Migraine Prevalence and Prevention (AMPP) Study
- (2016) Dawn C. Buse et al. HEADACHE
- The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies
- (2015) Michael J. Marmura et al. HEADACHE
- Predictors of placebo response in bipolar depression
- (2015) Andrew A. Nierenberg et al. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY
- What Do Patients Consider to Be the Most Important Outcomes for Effectiveness Studies on Migraine Treatment? Results of a Delphi Study
- (2014) Antonia F. H. Smelt et al. PLoS One
- Meta-Regression Analysis of Placebo Response in Antipsychotic Trials, 1970–2010
- (2013) Ofer Agid et al. AMERICAN JOURNAL OF PSYCHIATRY
- Dihydroergotamine: A Review of Formulation Approaches For the Acute Treatment of Migraine
- (2013) Stephen D. Silberstein et al. CNS DRUGS
- Understanding the time course of pharmacological effect: a PKPD approach
- (2011) Daniel F. B. Wright et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started